China’s biomanufacturing begins to use rice to make blood
April 8, 2025
Source: drugdu
71
"Rice makes blood", a concept that sounds "fairy tale", has now become a reality in a biopharmaceutical company in Wuhan. Human serum albumin manufactured in this way is not only safer and more environmentally friendly, but also has the advantages of large-scale production and low cost. It is expected to become an important solution to alleviate the shortage of human serum albumin in my country. At present, the human serum albumin product developed using this technology has completed phase III clinical trials and entered the new drug approval process. The team has built an intelligent factory with an annual output of 1 million injections and is building a large-scale production base with an annual output of 12 million injections.
https://finance.eastmoney.com/a/202504063365597167.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Midea Group established the Medical Division and released Midea Medical’s annual new products April 14, 2025
- Operating income of 3.07 billion yuan in 2024, a year-on-year increase of 13.32% April 14, 2025
- CanSino Biologics and Jiankai Technology have a strategic partnership to explore new mRNA vaccine tumor immunity solutions April 14, 2025
- Products will not be easily replaced, and the impact of tariffs is limited. April 14, 2025
- The United States may impose tariffs on drug imports. Many pharmaceutical companies responded with “close attention” April 11, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
